Daniel Andrés Nieva-Posso, Valeria Perea Ocampo, Daniel Alfonso Nieva Posso, Herney Andrés García-Perdomo
{"title":"Association between thyroid disorders and the Risk of developing prostate cancer: A systematic review and meta-analysis.","authors":"Daniel Andrés Nieva-Posso, Valeria Perea Ocampo, Daniel Alfonso Nieva Posso, Herney Andrés García-Perdomo","doi":"10.1177/03915603251336971","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the association between thyroid disorders and the Risk of developing prostate cancer.</p><p><strong>Methods: </strong>We conducted this review following the recommendations of the Cochrane Collaboration and the PRISMA Statement. From the moment to the present, we have conducted a search strategy using MEDLINE, WEB OF SCIENCE, and GOOGLE SCHOLAR. We included cohort and case-control studies that examined the relationship between thyroid disorders and the Risk of developing prostate cancer. We assessed the Risk of bias using the Newcastle Ottawa Quality Assessment scale. Meta-analysis was conducted in Review Manager 5.4.1 (Revman<sup>®</sup>).</p><p><strong>Results: </strong>We included nine studies in the analysis. The studies included were classified into two groups: those that studied hypothyroidism and those that studied hyperthyroidism. The results showed no association between thyroid abnormalities and prostate cancer risk, with an HR of 1.05 (95% CI: 0.90-1.22). Hyperthyroidism also showed no association with an HR 1.64 (95% CI: 1.00-2.69), characterized by increased serum T4 and decreased TSH. There was also no significant association with hypothyroidism, with an HR of 0.85 (95% CI: 0.67-1.10).</p><p><strong>Conclusion: </strong>Thyroid disorders were not associated with the Risk of developing prostate cancer.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251336971"},"PeriodicalIF":0.8000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251336971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To determine the association between thyroid disorders and the Risk of developing prostate cancer.
Methods: We conducted this review following the recommendations of the Cochrane Collaboration and the PRISMA Statement. From the moment to the present, we have conducted a search strategy using MEDLINE, WEB OF SCIENCE, and GOOGLE SCHOLAR. We included cohort and case-control studies that examined the relationship between thyroid disorders and the Risk of developing prostate cancer. We assessed the Risk of bias using the Newcastle Ottawa Quality Assessment scale. Meta-analysis was conducted in Review Manager 5.4.1 (Revman®).
Results: We included nine studies in the analysis. The studies included were classified into two groups: those that studied hypothyroidism and those that studied hyperthyroidism. The results showed no association between thyroid abnormalities and prostate cancer risk, with an HR of 1.05 (95% CI: 0.90-1.22). Hyperthyroidism also showed no association with an HR 1.64 (95% CI: 1.00-2.69), characterized by increased serum T4 and decreased TSH. There was also no significant association with hypothyroidism, with an HR of 0.85 (95% CI: 0.67-1.10).
Conclusion: Thyroid disorders were not associated with the Risk of developing prostate cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
